Note! Please note that this article is currently in the "Article in Press" stage and is not the final "Version of record". While it has been accepted, copy-edited, and formatted, however, it is still undergoing proofreading and corrections by the authors. Therefore, the text may still change before the final publication. Although "Articles in Press" may not have all bibliographic details available, the DOI and the year of online publication can still be used to cite them. The article title, DOI, publication year, and author(s) should all be included in the citation format. Once the final "Version of record" becomes available the "Article in Press" will be replaced by that.
Abstract
Background: Bipolar disorder is a complex mental disorder with a multifactorial pathology. Meta-analyses have shown that bipolar disorder is associated with imbalanced oxidative status, which can contribute to disease progression. Therefore, restoring the oxidative imbalance could be beneficial in the treatment of bipolar disorder. The firstline pharmacotherapy for bipolar disorder is lithium, anticonvulsants (particularly sodium valproate), and atypical antipsychotics. In the present review, we sought to describe the effects of these first-line medications on oxidative stress in bipolar patients.
Methods: We systematically searched databases through January 2022, including the Web of Science, PubMed, Scopus, and Embase, with no language or time restrictions. Eligible articles that assessed oxidative markers in bipolar patients following standard pharmacotherapy were included.
Result: According to Newcastle Ottawa and NIH scales, the overall quality of the included articles was low, and their heterogeneity prevented us from performing a meta-analysis.
Conclusion: We found that standard medications, especially lithium, can potentially alleviate oxidative imbalance based on a reduction in oxidative markers, such as TBARs and MDA, although randomized clinical trials are needed to unequivocally confirm these results.
